Antitumor activity also has been observed in phase I and II clinical trials with ganetespib or IPI-504 [16, 13], and a number of Hsp90 inhibitors - both as monotherapies and in combination with ALK tyrosine kinase inhibitors - are undergoing clinical trials for ALK-positive lung cancer patients. Here, ALK is linked to lung carcinoma.